Item 1.01 Entry into a Material Definitive Agreement.




As previously reported, on January 11, 2023, Tricida, Inc. (the "Company" or
"Debtor") filed a voluntary petition for relief under Chapter 11 of Title 11 of
the United States Code in the United States Bankruptcy Court for the District of
Delaware (the "Bankruptcy Court"), thereby commencing a Chapter 11 case for the
Company (Case No. 23-10024).

Starting on February 15, 2023 and concluding on February 20, 2023, as a part of
the Company's Bankruptcy Court-supervised sale process, the Company conducted an
auction (the "Auction") for the sale of substantially all of the Company's
assets (the "Assets"). The Debtor presented the Assets in two lots at the
Auction-the first ("Lot 1") primarily consisted of the Debtor's laboratory
equipment, and the second ("Lot 2") comprised substantially all of the Debtor's
other Assets, primarily composed of its intellectual property and certain
inventory. Debtor selected Liquidity Services, Inc. ("Liquidity Services") as
the highest or otherwise best offer for Lot 1 and Renibus Therapeutics, Inc.
("Renibus") as the highest or otherwise best offer for Lot 2. Following the
Auction, the Company continued to work with the winning bidders as well as
representatives of certain holders of the Company's subordinated notes and
representatives of the committee of unsecured creditors to overcome objections
and negotiate the definitive terms and documentation of these offers.

The Company entered into an asset purchase agreement, dated as of February 21,
2023, with Renibus (the "Renibus APA"), pursuant to which Renibus agreed to
acquire the intellectual property, inventory, and certain related assets
relating to Veverimer (formerly known as TRC101) (the "Compound"). The Renibus
APA provides for Renibus to make a $250,000 cash payment to the Debtor upon
closing. Additionally, the purchase price contemplates certain contingent,
milestone payments to the Debtor, totaling up to $152.5 million, subject to the
achievement of certain United States Food and Drug Administration regulatory
approvals and net sales milestones related to the Compound. Renibus also agreed
to use commercially reasonable efforts to develop (including seeking regulatory
approval for) and commercialize the Compound.

The Renibus APA contains customary representations, warranties, covenants, limitations of liability, and closing conditions. Additionally, the Company and/or Renibus may terminate the Renibus APA by mutual consent, if the closing date has not occurred on or before March 15, 2023, and upon certain other events.



The Company entered into an asset purchase agreement, dated as of February 22,
2023, with Liquidity Services (the "Liquidity Services APA"), pursuant to which
Liquidity Services agreed to acquire certain equipment for a purchase price of
$235,000, to be paid no later than five (5) business days after execution of the
Liquidity Services APA. The Liquidity Services APA also contains certain
customary representations, warranties, covenants, and limitations of liability.

The Bankruptcy Court entered orders on February 22, 2023 authorizing the Company to enter into and perform under the Renibus APA and the Liquidity Services APA.



The foregoing descriptions of the Renibus APA and the Liquidity Services APA do
not purport to be complete and are qualified in their entirety by reference to
Renibus APA and the Liquidity Services APA, copies of which are attached hereto
as Exhibits 10.1 and 10.2, respectively, and incorporated herein by reference.

Cautionary Statements Regarding Trading in the Company's Securities



The Company's securityholders are cautioned that trading in the Company's
securities during the pendency of the Chapter 11 case is highly speculative and
poses substantial risks. Trading prices for the Company's securities may bear
little or no relationship to the actual recovery, if any, by holders thereof in
the Company's Chapter 11 case. Accordingly, the Company urges extreme caution
with respect to existing and future investments in its securities.

Cautionary Note Regarding Forward-Looking Statements



This Current Report on Form 8-K and Exhibit 99.1 include forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Forward-looking statements
relate to expectations concerning matters that are not historical facts. Words
such as "projects," "believes," "anticipates," "plans," "expects," "intends,"
"may," "will," "could," "should," "would," and similar words and expressions are
intended to identify forward-looking statements. Forward-looking statements
involve risks and uncertainties that could cause actual results to differ
materially from those discussed in such forward-looking statements. Such risks
and uncertainties include, without limitation, the outcome of the Chapter 11
proceedings, the Company's contractual and financial obligations to key
suppliers and vendors; the Company's financial projections and cost estimates;
the Company's ability to raise additional funds; and risks associated with the
Company's business prospects, financial results and business operations. These
and other factors that may affect the


--------------------------------------------------------------------------------

Company's future business prospects, results and operations are identified and
described in more detail in the Company's filings with the Securities and
Exchange Commission (the "SEC"), including the Company's most recent Annual
Report filed on Form 10-K and the subsequently filed Quarterly Report(s) on Form
10-Q. You should not place undue reliance on these forward-looking statements,
which speak only as of the date of this Form 8-K. Except as required by
applicable law, the Company does not intend to update any of the forward-looking
statements to conform these statements to actual results, later events or
circumstances or to reflect the occurrence of unanticipated events.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.

Exhibit Number              Description

                              Asset Purchase Agreement, dated February 21, 2023, by and between Tricida,
10.1                        Inc. and Renibus Therapeutics, Inc.

                              Asset Purchase Agreement, dated February 22, 2023, by and between Tricida,
10.2                        Inc. and Liquidity Services.

104                         Cover Page Interactive Data File (embedded

within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses